Sandra M. Herrmann

10.3k total citations
168 papers, 5.9k citations indexed

About

Sandra M. Herrmann is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Sandra M. Herrmann has authored 168 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Pulmonary and Respiratory Medicine, 40 papers in Molecular Biology and 39 papers in Oncology. Recurrent topics in Sandra M. Herrmann's work include Renal and Vascular Pathologies (27 papers), Renal Diseases and Glomerulopathies (17 papers) and Renal cell carcinoma treatment (16 papers). Sandra M. Herrmann is often cited by papers focused on Renal and Vascular Pathologies (27 papers), Renal Diseases and Glomerulopathies (17 papers) and Renal cell carcinoma treatment (16 papers). Sandra M. Herrmann collaborates with scholars based in United States, Germany and China. Sandra M. Herrmann's co-authors include Lilach O. Lerman, Amir Lerman, Stephen C. Textor, Ahmed Saad, Joerg Herrmann, Sandhya Manohar, Alfonso Eirin, Claudio Napoli, Nelson Leung and Rhian M. Touyz and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Sandra M. Herrmann

155 papers receiving 5.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sandra M. Herrmann United States 48 1.8k 1.3k 1.2k 960 946 168 5.9k
David S. Geller United States 38 3.1k 1.7× 1.8k 1.4× 1.7k 1.4× 966 1.0× 826 0.9× 130 7.2k
Theodore M. Danoff United States 26 2.7k 1.5× 1.0k 0.8× 1.1k 0.9× 1.1k 1.1× 413 0.4× 47 6.7k
Wim J. Sluiter Netherlands 55 2.2k 1.2× 2.8k 2.2× 1.4k 1.1× 1.6k 1.6× 1.1k 1.1× 252 9.8k
О. Л. Барбараш Russia 25 2.4k 1.3× 972 0.8× 2.4k 1.9× 831 0.9× 1.6k 1.7× 714 6.3k
Hirokazu Okada Japan 36 3.4k 1.9× 1.3k 1.0× 1.7k 1.3× 957 1.0× 1.2k 1.2× 220 8.9k
Keiichi Ito Japan 34 1.3k 0.7× 932 0.7× 943 0.8× 572 0.6× 887 0.9× 349 4.3k
Zamaneh Kassiri Canada 48 2.4k 1.3× 1.3k 1.0× 869 0.7× 1.0k 1.0× 3.1k 3.2× 105 7.3k
Solbritt Rantapää‐Dahlqvist Sweden 61 1.6k 0.9× 710 0.6× 958 0.8× 1.1k 1.2× 1.2k 1.2× 248 12.6k
Toshiharu Ishii Japan 49 1.6k 0.8× 1.5k 1.2× 1.3k 1.0× 789 0.8× 1.1k 1.1× 155 5.6k
Andrew I. Schafer United States 51 2.2k 1.2× 1.0k 0.8× 579 0.5× 381 0.4× 1.1k 1.2× 112 7.0k

Countries citing papers authored by Sandra M. Herrmann

Since Specialization
Citations

This map shows the geographic impact of Sandra M. Herrmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra M. Herrmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra M. Herrmann more than expected).

Fields of papers citing papers by Sandra M. Herrmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra M. Herrmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra M. Herrmann. The network helps show where Sandra M. Herrmann may publish in the future.

Co-authorship network of co-authors of Sandra M. Herrmann

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra M. Herrmann. A scholar is included among the top collaborators of Sandra M. Herrmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra M. Herrmann. Sandra M. Herrmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Farina, Juan, Kamal Awad, Christopher Kanaan, et al.. (2025). Diagnostic and Prognostic Value of High‐Sensitivity Troponin T for Cardiovascular Outcomes in Patients Receiving Immune Checkpoint Inhibitor Therapy. Journal of the American Heart Association. 15(6). e041680–e041680. 1 indexed citations
2.
Silva, Verônica T. Costa e, et al.. (2025). Update on the Assessment of GFR in Patients with Cancer. Kidney360. 6(5). 861–870.
3.
Herrmann, Sandra M., et al.. (2025). WCN25-1014 TECLISTAMAB AND NIVOLUMAB: A SYNERGISTIC KIDNEY STORM - A CASE OF ACUTE INTERSTITIAL NEPHRITIS WITH DUAL IMMUNOTHERAPY. Kidney International Reports. 10(2). S24–S24.
4.
Lieske, John C., et al.. (2024). Biomarker-guided infliximab therapy for immune checkpoint inhibitor-induced acute interstitial nephritis. Nephrology Dialysis Transplantation. 40(3). 602–604. 1 indexed citations
5.
Scalia, Isabel G., M.L. González Pereyra, Yan Wang, et al.. (2024). The impact of peptide receptor radionucleotide therapy with Lutetium-177 DOTATATE on cardiac metastases in neuroendocrine tumors. European Heart Journal. 45(Supplement_1).
6.
Vaughan, Lisa E., et al.. (2024). Incidence of acute kidney injury in patients with relapsed and refractory multiple myeloma treated with teclistamab vs chimeric antigen receptor T-cell therapy.. Journal of Clinical Oncology. 42(16_suppl). 7542–7542. 2 indexed citations
7.
Herrmann, Sandra M., Ala Abudayyeh, Shruti Gupta, et al.. (2024). Diagnosis and management of immune checkpoint inhibitor–associated nephrotoxicity: a position statement from the American Society of Onco-nephrology. Kidney International. 107(1). 21–32. 12 indexed citations
8.
Barreto, Jason N., Kristin C. Mara, Paul J. Hampel, et al.. (2024). Rechallenge With High-Dose Methotrexate After Treatment With Glucarpidase in Adult Patients With Lymphoma. JCO Oncology Practice. 20(6). 797–807. 4 indexed citations
9.
Pandey, Shubhi, et al.. (2023). Management of hypertension in patients with cancer: challenges and considerations. Clinical Kidney Journal. 16(12). 2336–2348. 10 indexed citations
10.
Sise, Meghan E., Qiyu Wang, Harish Seethapathy, et al.. (2023). Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis. Journal for ImmunoTherapy of Cancer. 11(1). e006222–e006222. 23 indexed citations
11.
Csilla, Semánová, Gergő József Szöllösi, Greet Cardon, et al.. (2023). Differences in Anthropometric Parameters of Children in Six European Countries. Children. 10(6). 983–983.
12.
Zhang, Pingchuan, et al.. (2022). Unusual Course of Paraneoplastic IgA Nephropathy Associated With Squamous Cell Lung Cancer. Journal of the American Society of Nephrology. 33(11S). 373–373.
13.
Herrmann, Sandra M., et al.. (2021). Successful Treatment of Pembrolizumab-Induced Severe Capillary Leak Syndrome and Lymphatic Capillary Dysfunction. SHILAP Revista de lepidopterología. 5(3). 670–674. 16 indexed citations
14.
Hickson, LaTonya J., Xiaohui Bian, Sabena M. Conley, et al.. (2021). A Systematic Review and Meta-Analysis of Cell-Based Interventions in Experimental Diabetic Kidney Disease. Stem Cells Translational Medicine. 10(9). 1304–1319. 36 indexed citations
15.
Vaughan, Lisa E., Collin M. Costello, Charat Thongprayoon, et al.. (2020). Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single‐center analysis. Cancer. 126(21). 4780–4787. 27 indexed citations
16.
Bian, Xiaohui, Tomás P. Griffin, Xiangyang Zhu, et al.. (2019). Senescence marker activin A is increased in human diabetic kidney disease: association with kidney function and potential implications for therapy. BMJ Open Diabetes Research & Care. 7(1). e000720–e000720. 44 indexed citations
17.
18.
Park, Moo Yong, Sandra M. Herrmann, Ahmed Saad, et al.. (2014). Biomarkers of Kidney Injury and Klotho in Patients with Atherosclerotic Renovascular Disease. Clinical Journal of the American Society of Nephrology. 10(3). 443–451. 37 indexed citations
19.
Herrmann, Sandra M., Ardan M. Saguner, Ana I. Flores, et al.. (2013). Primary Proteasome Inhibition Results in Cardiac Dysfunction. European Journal of Heart Failure. 15(6). 614–623. 61 indexed citations
20.
Herrmann, Sandra M., Ardan M. Saguner, Daniele Versari, et al.. (2007). Chronic Proteasome Inhibition Contributes to Coronary Atherosclerosis. Circulation Research. 101(9). 865–874. 86 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David S. Geller Breakdown of academic impact, for papers by Theodore M. Danoff Breakdown of academic impact, for papers by Wim J. Sluiter Breakdown of academic impact, for papers by О. Л. Барбараш Breakdown of academic impact, for papers by Hirokazu Okada Breakdown of academic impact, for papers by Keiichi Ito Breakdown of academic impact, for papers by Zamaneh Kassiri Breakdown of academic impact, for papers by Solbritt Rantapää‐Dahlqvist Breakdown of academic impact, for papers by Toshiharu Ishii Breakdown of academic impact, for papers by Andrew I. Schafer
Rankless by CCL
2026